BCAX biotech catalysts & pipeline

BICARA THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

ficerafusp alfa — Initial data

H2 2026

• Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in the second half of 2026.

Source filing

ficerafusp alfa — Interim data

mid-2027

On track for substantial enrollment of pivotal FORTIFI-HN01 study by year-end, enabling topline results from interim analysis in mid-2027; initiated FORTIFI-FLEX alternate dosing study

Source filing

Explore the free biotech catalyst calendar